Breaking Down Novogene Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Novogene Co., Ltd. (688315.SS) is a buy, hold or simply a story in transition? Dive into a data-rich breakdown that opens with topline momentum-TTM revenue of CNY 2.17 billion and Q3 2025 revenue of CNY 540.65 million, up 3.86% and 3.47% year-over-year respectively-and tracks profitability signals like TTM EPS of CNY 0.49 (Q1 2025 EPS of CNY 0.08) and a 2024 gross margin of 43.7% alongside a net profit margin of 9.65% in 2024; balance-sheet snapshots show cash and equivalents of CNY 494.14 million but also sizable accounts receivable of CNY 692.96 million, a market cap of CNY 5.43 billion (share price CNY 13.41), a P/S of 2.50 and an implied P/E near 27.33, while operational metrics-revenue per employee of CNY 986,770 and overseas revenue at 49.3%-and forward projections (revenues of CNY 2.270B / 2.554B / 2.887B for 2025-2027 with net profits of CNY 222M / 253M / 284M) frame both the growth runway and the risks tied to receivables, limited debt disclosure and regional concentration-read on to see how these concrete figures translate into investor-relevant insights.

Novogene Co., Ltd. (688315.SS) - Revenue Analysis

• TTM Revenue (9/30/2025): CNY 2.17 billion (+3.86% YoY)
• Q3 2025 Revenue: CNY 540.65 million (+3.47% YoY)
• 2024 Annual Revenue: CNY 2.11 billion (+5.45% YoY)
• Revenue per employee: ~CNY 986,770 (2,202 employees)
• Price-to-Sales (P/S) ratio: 2.50
• Market capitalization: ~CNY 5.43 billion (share price CNY 13.41)

• Revenue growth profile: modest single-digit expansion, decelerating from 2024's 5.45% to 3.86% TTM.
• Efficiency: revenue per employee (~CNY 986.8k) indicates per-head productivity aligned with mid-tier biotech services peers.
• Valuation signal: P/S of 2.50 and market cap CNY 5.43bn imply moderate market expectations relative to revenue base.
• Quarterly consistency: Q3 2025 growth (+3.47%) mirrors TTM trend, suggesting stable demand rather than episodic spikes.

Novogene Co., Ltd. (688315.SS) - Profitability Metrics

Key profitability figures and trends for Novogene across recent reporting periods, highlighting quarter-over-quarter and year-over-year performance.

• Q1 2025 net income: CNY 33.88 million (Q1 2024: CNY 27.32 million).
• Q1 2025 basic EPS: CNY 0.08 (Q1 2024: CNY 0.07).
• TTM EPS as of March 2025: CNY 0.49.
• Gross profit margin (2024): 43.7% (+1.0 ppt YoY).
• Net profit margin (2024): 9.65% (+0.50 ppt YoY).

• Q1 2025 shows rising profitability vs. Q1 2024 in absolute net income and EPS, with net income increasing by CNY 6.56 million (24.0% YoY).
• Implied Q1 2025 revenue (based on reported net income and the 6.75% margin) is approximately CNY 502.37 million, indicating scale relative to earnings.
• 2024 margins improved: gross margin expanded by 1.0 ppt and net margin by 0.50 ppt, reflecting margin recovery or operational leverage.
• TTM EPS of CNY 0.49 as of March 2025 signals an upward earnings trend compared with quarterly EPS levels.

Mission Statement, Vision, & Core Values (2026) of Novogene Co., Ltd.

Novogene Co., Ltd. (688315.SS) - Debt vs. Equity Structure

Assessment of Novogene's capital structure as of September 30, 2025 highlights clear strengths in liquidity but important gaps in publicly available leverage information.

• Cash and cash equivalents: CNY 494.14 million (up 22.63% year-over-year)
• Market capitalization: CNY 5.43 billion
• Total assets and total liabilities: not specified in available data
• Detailed debt breakdown (short-term debt, long-term debt, covenants): not disclosed

Implications for investors:

• The 22.63% rise in cash reserves signals a conservative financing posture and provides flexibility for operations, R&D, or debt reduction.
• Market cap of CNY 5.43 billion indicates a meaningful equity base relative to available cash, but without asset/liability figures the debt-to-equity ratio cannot be reliably calculated.
• Absence of line-item debt disclosures restricts assessment of leverage, interest coverage, covenant risk, and refinancing exposure.
• Investors should seek supplemental filings or disclosures (e.g., interim reports, notes to financial statements) to quantify debt levels before forming a view on financial risk.

For further context on Novogene's strategic orientation and governance that may affect financing choices, see Mission Statement, Vision, & Core Values (2026) of Novogene Co., Ltd.

Novogene Co., Ltd. (688315.SS) - Liquidity and Solvency

• Cash and cash equivalents: CNY 494.14 million (9/30/2025).
• Accounts receivable: CNY 692.96 million (9/30/2025) - a sizable level of outstanding payments relative to cash on hand.
• Year-over-year cash reserve change: +22.63% - indicates improved cash generation or cash management versus the prior year.
• Market capitalization: CNY 5.43 billion - reflects investor valuation and perceived financial stability.
• Cash conversion cycle and current ratio: not provided - limits short-term liquidity analysis.
• Detailed short-term and long-term debt data: not provided - restricts a full solvency assessment.

• Positive: CNY 494.14M cash plus a 22.63% YoY increase suggests strengthening cash buffers and better cash flow management.
• Warning: Accounts receivable (CNY 692.96M) exceed cash on hand, signaling collection risk or extended receivables conversion.
• Analytical gap: Missing cash conversion cycle, current ratio, and debt breakdown prevents a complete view of short- and long-term solvency.
• Market signal: CNY 5.43B market cap indicates market confidence but should be weighed against the limited transparency on liabilities.

Novogene Co., Ltd. (688315.SS) Valuation Analysis

• P/S = 2.50: suggests market values each yuan of Novogene revenue at 2.5×, a middling premium that implies balanced growth expectations without aggressive optimism.
• P/E ≈ 27.33 on TTM EPS of CNY 0.49: indicates investors pay ~27× recent earnings - moderate for a biotech/genomics services firm where future growth typically justifies higher multiples.
• Market cap CNY 5.43B at CNY 13.41/share: positions Novogene as a small-to-mid cap in the China genomics sector, susceptible to sector sentiment and R&D cycle news.
• Revenue per employee ~CNY 986,770: points to efficient utilization of staff and operational leverage potential; high productivity can support margin expansion if revenue scales.
• Cash reserves up 22.63% YoY: improves balance-sheet flexibility, supports R&D and M&A optionality, and can reduce perceived financial risk-positive for valuation.
• Limited debt detail: the absence of transparent or detailed leverage metrics constrains enterprise-value based comparisons (EV/EBITDA, net-debt adjustments), limiting full valuation precision.

Novogene Co., Ltd. (688315.SS) - Risk Factors

Assessing Novogene Co., Ltd. (688315.SS) requires focused attention on several key risk vectors where data gaps and business realities materially affect investor perspective.

• The absence of detailed debt information poses challenges in assessing financial risk and leverage; both short-term and long-term debt line items are not fully disclosed.
• The company reports significant accounts receivable of CNY 692.96 million, which may indicate potential cash flow and working capital strains if collection deteriorates.
• Heavy reliance on the Chinese market leaves revenue and margins exposed to regional economic cycles, policy shifts, and local regulatory enforcement.
• Intense competition in the genomic sequencing and life-sciences services market could compress pricing, reduce market share, and pressure R&D returns.
• Lack of granular disclosure on operational risks (e.g., supply chain disruptions, reagent shortages, instrument downtime) limits the ability to stress-test operational continuity.
• Concentration risks (customers, suppliers, geographies) are amplified when public disclosures do not include counterparty-level or segment-level concentration metrics.

• Liquidity risk: Elevated receivables relative to cash balances (given limited cash disclosure) could increase rollover risk for operating cycles and capex funding.
• Leverage assessment gap: Without clear short-term and long-term debt details, leverage ratios (debt/EBITDA, current ratio) cannot be reliably calculated, hampering credit-risk and covenant analysis.
• Regulatory and policy risk: Any tightening of data, biotech export controls, or approval pathways in China can have an outsized effect on timelines and costs for clinical/genomic services.
• Competitive risk: Global and domestic entrants offering lower-cost sequencing, bundled analytics, or integrated diagnostics may erode pricing power.
• Operational blind spots: Unspecified supply-chain and operational risk disclosures make it difficult to simulate scenarios such as reagent shortages, equipment failures, or staffing constraints.

For context on the company's stated direction and values, see: Mission Statement, Vision, & Core Values (2026) of Novogene Co., Ltd.

Novogene Co., Ltd. (688315.SS) - Growth Opportunities

• New Japan laboratory enhances access to APAC clinical and research customers and supports partnerships with local biopharma.
• Network coverage across ~90 countries enables scalable cross-border services and logistics efficiencies.
• Listing on the SSE STAR Market (April 2025) provides incremental capital for capacity expansion, R&D, and M&A.
• Core competency in next-generation sequencing (NGS) positions Novogene to capture rising genomic testing demand in clinical, agricultural, and pharma sectors.
• Product innovation and market entry initiatives target higher-margin services and recurring revenue streams.

• Capital infusion from the STAR Market listing supports scaling of sequencing capacity, bioinformatics platforms, and regional lab openings.
• NGS-driven demand vectors include precision oncology, reproductive health, large-scale population genomics, and agricultural genomics.
• Targeted product development and localized service offerings are expected to improve client retention and average revenue per customer.